ASPE · Aspen Neuroscience, Inc. · Investor Relations
You came from your AI assistant. Add Equibles to it and ask about this data directly, free.
Press releases and events scraped from the company’s investor relations website. Past events open our own call or event page when we host one; otherwise listings link to the original source.
Recent news
| Date | Headline |
|---|---|
| 2026-10-30 |
Aspen Neuroscience Announces Pricing of Initial Public Offering
SAN DIEGO, Oct. 29, 2026 (GLOBE NEWSWIRE) -- Aspen Neuroscience, Inc. (Nasdaq: ASPE), a clinical-stage regenerative medicine biotechnology company developing autologous cell therapies for Parkinson’s disease (PD), today announced the pricing of its initial public offering of 9,375,000 shares of |
| 2026-09-18 |
Aspen Neuroscience Announces Publication of Sasineprocel Preclinical Data in "Cell Stem Cell"
Peer-reviewed findings describe reproducible manufacturing, leading-edge genomic quality controls and preclinical evidence supporting clinical development of an autologous iPSC-derived neuron replacement therapy for Parkinson’s disease, now entering Phase 3 SAN DIEGO, Sept. |
| 2026-07-30 |
Aspen Neuroscience Receives FDA Regenerative Medicine Advanced Therapy (RMAT) Designation for Sasineprocel (ANPD001) to Treat Parkinson’s Disease
SAN DIEGO, July 30, 2026 / PRNewswire / — Aspen Neuroscience, Inc., a clinical-stage regenerative medicine biotechnology company developing personalized, autologous cell therapies, today announced that sasineprocel (ANPD001), its lead investigational product, for the treatment of Parkinson’s |
| 2026-06-30 |
Aspen Neuroscience Announces Completion of Cohort 3 and 4 Dosing in Aspiro Phase 1/2a Trial of Sasineprocel for Parkinson’s Disease
Advancement of commercial-ready formulation supports scalability and late-stage development SAN DIEGO, June 30, 2026 / PRNewswire / — Aspen Neuroscience, Inc., a clinical-stage regenerative medicine biotechnology company developing personalized, autologous cell therapies, today announced completion |
| 2026-03-18 |
Aspen Neuroscience Announces Positive 12‑Month Data from its ASPIRO Clinical Trial in a Late‑Breaking Oral Presentation at the AD/PDTM 2026 International Conference on Alzheimer’s and Parkinson’s Diseases
Results Show Continued Safety, Tolerability, and Sustained Clinical Benefit Including Improvements in Function, Physician- and Patient-Reported Outcomes, and Quality-of-Life This Personalized Autologous Cell Therapy Aims to Replace and Restore the Damaged Neural Circuitry in Parkinson’s |
| 2026-03-12 |
Aspen Receives Adoption of Sasineprocel as the Official Nonproprietary Naming of ANPD001, its Investigational Autologous Cell Therapy for the Treatment of Parkinson’s Disease
Approved for Use By both the World Health Organization’s International Nonproprietary Names (WHO-INN) and the American Medical Association’s United States Adopted Names (AMA-USAN) Council SAN DIEGO, Mar. 12, 2026 / PRNewswire / — Aspen Neuroscience, Inc., a clinical‑stage biotechnology company |
| 2026-01-08 |
Aspen Neuroscience Completes Phase 1/2a ASPIRO Trial Cohort Three Dosing and State-of-the-Art Manufacturing Expansion, Paving the Way for Developing Transformative Therapies for Patients
Facility Enters Qualification to Support Late‑Stage Pivotal Manufacturing and Commercial Readiness SAN DIEGO, Jan. 8, 2026 / PRNewswire / — Aspen Neuroscience, Inc., a clinical‑stage biotechnology company pioneering autologous regenerative therapies, today announced completion of Cohort |
| 2025-11-20 |
Aspen Neuroscience Announces $115 Million Series C Financing to Accelerate Personalized Cell Therapy Programs
SAN DIEGO, Nov. 20, 2025 / PRNewswire / — Aspen Neuroscience, Inc., a clinical-stage biotechnology company pioneering autologous regenerative therapies, today announced the closing of a $115 million Series C financing round. This significant investment will fuel the continued clinical development |
| 2025-09-25 |
Aspen Neuroscience Initiates Cohort 3 in ASPIRO Phase 1/2a Trial, Highlighting Commercial Formulation of ANPD001 and Its Transformative Potential for Parkinson’s Disease
SAN DIEGO, September 25, 2025 / PRNewswire / — Aspen Neuroscience, Inc., a clinical-stage biotechnology company pioneering autologous regenerative therapies, today announced the initiation of Cohort 3* in its ASPIRO Phase 1/2a clinical trial of ANPD001, the company’s personalized dopaminergic |
| 2025-06-09 |
Aspen Neuroscience to Present at the International Society for Stem Cell Research (ISSCR) 2025 Annual Meeting
Presentation of Data from Clinical Trial of Aspen’s Autologous iPSC-derived Approach for Neuronal Replacement Therapy in Parkinson’s Disease SAN DIEGO, June 9, 2025 / PRNewswire / — Aspen Neuroscience, Inc. announced its participation in “Illuminating the Future,” the International Society for Stem |